Investment Rating - The investment rating for the company is "Buy" with a target price set for the next six months [6][14]. Core Insights - The company achieved a record high revenue of 41.97 billion yuan in Q3 2025, marking a 27.5% increase quarter-on-quarter and a 27.2% increase year-on-year. However, net profit for the same quarter was 3.17 billion yuan, reflecting a 16.4% year-on-year decline [1][2]. - The HNB (Heated Not Burned) business saw a significant increase in shipment volumes, contributing to the overall revenue growth. The company is also expanding its self-owned brand business and enhancing localized marketing efforts [2][5]. - The medical aerosol business has made a breakthrough with the submission of an ANDA application for Breo® Ellipta®, which, if approved, could provide a 180-day market exclusivity in the U.S. This product is expected to generate significant sales in the future [4][5]. Summary by Sections Financial Performance - For the first three quarters of 2025, the company reported revenues of 102.10 billion yuan, a year-on-year increase of 21.8%. Adjusted net profit was 11.82 billion yuan, a slight increase of 0.1% year-on-year [1]. - In Q3 2025, the company achieved revenues of 41.97 billion yuan, with an adjusted net profit of 4.44 billion yuan, reflecting a 4.0% year-on-year increase [1][2]. Business Growth - The company’s HNB and electronic vaporization businesses both experienced growth, with strategic clients successfully launching new products in major global markets [2]. - The GloHilo product line is being introduced in Italy, Poland, and Serbia, aiming to reach 50 million adult consumers of smoke-free products by 2030 [3]. Future Outlook - The company is expected to see significant contributions from the HNB business starting in 2026, with adjusted net profit forecasts for 2025-2027 revised to 13.92 billion, 20.23 billion, and 27.59 billion yuan respectively [5].

Core Viewpoint - Guojin Securities maintains a "Buy" rating for Smoore International (06969), projecting EPS for 2025-2027 to be 0.22, 0.39, and 0.59 yuan respectively, with corresponding PE ratios of 67, 37, and 25 times at the current stock price [1] Financial Performance Summary - For Q1-Q3 2025, the company achieved revenue of 10.21 billion yuan, a year-on-year increase of 21.8%, with net profit and adjusted net profit (excluding stock incentive expenses) at 809 million and 1.182 billion yuan, reflecting a year-on-year decrease of 23.8% and an increase of 0.1% respectively [1] - In Q3 2025, the company reported revenue of 4.197 billion yuan, a year-on-year increase of 27.2%, with net profit and adjusted net profit at 317 million and 444 million yuan, showing a year-on-year decrease of 16.4% and an increase of 4.0% respectively [1][2] Business Segment Insights - The HNB (Heated Not Burn) business is expected to significantly contribute to revenue, with the launch of the hilo product in Japan and Poland driving sales growth, alongside increasing regulatory scrutiny on illegal products in Europe and the US [1] - The vaping business is anticipated to achieve double-digit growth in Q3 2025, benefiting from market shifts in Europe and increased enforcement against illegal products in the US [1] - The company is focusing on the iteration and expansion of its own brand series, with a steady increase in market share, and expects favorable growth in its APV (Advanced Personal Vaporizer) business [1][2] Profitability Outlook - Adjusted net profit for Q3 2025 increased by 4.0% to 444 million yuan, with an adjusted net profit margin of 10.6%, down from 11.5% in Q3 2024 [2] - Despite a year-on-year decline in profit margin, the overall performance remains strong, with future profit elasticity expected due to the anticipated increase in profitability from HNB products as sales volume grows [2] - The company is also increasing R&D investments in medical nebulization, with recent FDA acceptance of a subsidiary's abbreviated new drug application indicating progress in this area [2] Market Expansion and Growth Potential - The expansion of the legal vaping market in Europe and the US is a prevailing trend, with the HNB product glo hilo starting promotions in Poland, indicating potential for global sales growth [2] - The company is positioned as a unique player deeply integrated into the supply chains of both vaping and HNB products, suggesting a clear path for future growth [2]

Core Viewpoint - Guojin Securities maintains a "Buy" rating for Smoore International (06969), projecting EPS for 2025-2027 to be 0.22, 0.39, and 0.59 yuan respectively, with current stock prices corresponding to PE ratios of 67, 37, and 25 times [1] Financial Performance - For Q1-Q3 2025, the company achieved revenue of 10.21 billion yuan, a year-on-year increase of 21.8%, with net profit and adjusted net profit (excluding stock incentive costs) at 808 million and 1.182 billion yuan, reflecting a year-on-year decrease of 23.8% and an increase of 0.1% respectively [1] - In Q3 2025, the company reported revenue of 4.197 billion yuan, a year-on-year increase of 27.2%, with net profit and adjusted net profit at 317 million and 444 million yuan, showing a year-on-year decrease of 16.4% and an increase of 4.0% respectively [1][2] Business Segments - The HNB (Heat-not-Burn) business is expected to significantly contribute to revenue, with the launch of the hilo product in Japan and Poland driving sales growth [1] - The vaping business is anticipated to achieve double-digit growth in Q3 2025, benefiting from regulatory changes in Europe and increased enforcement against illegal products in the U.S. [1] - The company is focusing on the iteration and expansion of its own brand series, with a steady increase in market share for its OBM (Own Brand Manufacturing) business [1] Profitability Outlook - The adjusted net profit for Q3 2025 increased by 4.0% to 444 million yuan, with an adjusted net profit margin of 10.6%, slightly down from 11.5% in Q3 2024 [2] - Despite a decline in profit margin, the overall performance remains strong, with future profit elasticity expected due to the anticipated increase in HNB business profitability as sales volume grows [2] Market Expansion - The expansion of the legal vaping market in Europe and the U.S. is a significant trend, with the HNB product glo hilo starting promotions in Poland, indicating potential for global sales growth [3] - The company is positioned as a unique player deeply involved in the supply chains of both vaping and HNB products, suggesting a clear path for future growth [3]

Investment Rating - The investment rating for Smoore International (6969.HK) is not explicitly stated in the provided documents, but the report indicates a positive outlook based on revenue growth and market opportunities [1]. Core Insights - Smoore International reported a record high revenue of 10.21 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 21.8%. The total comprehensive income for the period was 785 million yuan, down 25.5% year-on-year. In Q3 alone, revenue reached 4.196 billion yuan, with a quarter-on-quarter increase of 27.5% and a year-on-year increase of 27.2% [1]. - The company is expected to benefit from stringent global regulations, particularly in the vaping sector, with steady growth anticipated in the U.S. and high growth in Europe due to the introduction of compliant products [2]. - The HNB (Heated Not Burned) segment is gradually contributing to revenue growth, with expectations for increased shipments and market expansion in key regions like Poland and Italy [2]. - The adjusted net profit margin for Q3 2025 was approximately 10.6%, down from 13.0% in Q3 2024, primarily due to changes in product mix affecting gross margins. However, the company is optimizing its expense ratios, which are expected to decline as HNB product sales increase [3]. Financial Summary - For the fiscal years 2024 to 2027, the projected total revenue is as follows: - 2024: 11.799 billion yuan - 2025: 14.610 billion yuan - 2026: 17.669 billion yuan - 2027: 21.253 billion yuan - The expected growth rates year-on-year are 6% for 2024, 24% for 2025, 21% for 2026, and 20% for 2027 [4]. - The projected net profit attributable to the parent company is: - 2024: 1.303 billion yuan - 2025: 1.088 billion yuan - 2026: 2.040 billion yuan - 2027: 3.050 billion yuan - The corresponding P/E ratios are projected to be 57.75X for 2024, 83.46X for 2025, 44.52X for 2026, and 29.78X for 2027 [4][6].

报告提到，虽然思摩尔国际第三季收入较市场预期高至少10%，但盈利胜市场预期的幅度则较小。关键 正面因素在于加热烟业务开始好转，且增长动能不仅来自单一客户英美烟草(British American Tobacco)。尽管盈利能见度仍然有限，集团核心业务改善的趋势，应有助其股价回稳。 大和发布研报称，思摩尔国际(06969)第三季总收入同比增长27%至42亿元人民币，创历史新高，并是自 2021年以来最大升幅。该行将思摩尔国际2025至27年每股盈利预测下调6%至20%，预期利润率恢复步 伐会较缓慢;重申"跑赢大市"评级，目标价由16港元微升至17港元。管理层首次作出指引，料全年加热 烟(HNB)业务将贡献至少12亿元人民币收入，该行估算相当于约8%销售额。 ...

Core Viewpoint - Daiwa's report indicates that Smoore International (06969) achieved a record high total revenue of 4.2 billion RMB in Q3, representing a year-on-year growth of 27%, the largest increase since 2021 [1] Financial Performance - Q3 revenue exceeded market expectations by at least 10%, although the profit beat was modest [1] - The company's management provided guidance indicating that the heated tobacco (HNB) business is expected to contribute at least 1.2 billion RMB in revenue for the year, which is approximately 8% of total sales [1] Market Outlook - Daiwa has lowered its earnings per share forecast for Smoore International for 2025 to 2027 by 6% to 20%, anticipating a slower recovery in profit margins [1] - Despite limited visibility on profitability, the trend of improvement in the core business is expected to support a stabilization in the company's stock price [1] Investment Rating - Daiwa maintains an "Outperform" rating on Smoore International, with a slight increase in the target price from 16 HKD to 17 HKD [1]

Core Viewpoint - Daiwa's research report indicates that Smoore International's total revenue for Q3 increased by 27% year-on-year to HKD 4.2 billion, marking a historical high and the largest increase since 2021 [1] Group 1: Financial Performance - The management provided guidance for the first time, expecting the heated tobacco (HNB) business to contribute at least HKD 1.2 billion in revenue for the full year, which is approximately 8% of total sales [1] - The key positive factor is the improvement in the HNB business, with growth momentum not solely reliant on a single client, British American Tobacco [1] Group 2: Market Outlook - Despite limited visibility on profitability, the trend of improvement in the core business is expected to help stabilize the company's stock price [1] - Daiwa has revised its earnings per share forecast for Smoore International for 2025 to 2027 down by 6% to 20%, anticipating a slower recovery in profit margins [1] Group 3: Investment Rating - Daiwa maintains a "Outperform" rating for Smoore International, with a slight increase in the target price from HKD 16 to HKD 17 [1]

Group 1: Market Performance - The consumption ETF (159928) rose over 1.3% today, with a trading volume exceeding 520 million yuan, marking a net inflow of over 440 million yuan yesterday and an additional 60 million yuan today, achieving eight consecutive days of capital inflow [1] - The latest scale of the consumption ETF (159928) has surpassed 19.9 billion yuan, nearing the 20 billion yuan mark, significantly leading its peers [1] Group 2: Hong Kong Market Insights - The Hong Kong consumption 50 ETF (159268) experienced a slight increase of 0.1%, with a trading volume exceeding 30 million yuan, accumulating over 12 million yuan in net inflow over the past 20 days [3] - Key component stocks showed mixed performance, with notable gains in brands like Bling and Pop Mart, while companies like Mixue Group and Anta Sports saw declines [3] Group 3: Consumer Trends and Opportunities - The upcoming Double 11 shopping festival is expected to boost consumer spending, with Alibaba's Taobao implementing significant subsidy measures to enhance sales [6][8] - The retail sector is anticipated to perform in line with expectations during the National Day holiday, driven by customer traffic, although average spending per customer remains under pressure [6] Group 4: Investment Outlook - The current market environment presents a rebound opportunity due to low valuations and a clean slate for companies, with expectations of improved fundamentals in sectors like beer and dairy [8] - Structural growth remains robust, particularly among younger consumers and in emerging markets, with certain stocks showing reasonable valuations and high growth potential over the next three years [8] - Four categories of investment opportunities are highlighted for the next six months, focusing on low absolute valuations, historical valuation comparisons, high growth certainty, and short-term policy-driven sectors [8] Group 5: ETF Composition - The consumption ETF (159928) has a significant concentration in its top ten holdings, with over 68% weight, including leading liquor companies and major consumer goods firms [10] - Notable stocks in the ETF include Wuliangye, Kweichow Moutai, and Yili, each holding substantial weight in the index [11]

Core Viewpoint - The company reported a significant revenue increase in Q3 2025, driven by the HNB and vaping business, despite a decline in net profit due to initial low-margin sales and ongoing investments in R&D [1][2] Financial Performance - For Q1-Q3 2025, the company achieved revenue of 10.21 billion yuan, a year-on-year increase of 21.8%, with net profit of 809 million yuan, down 23.8% [1] - In Q3 2025, revenue reached 4.197 billion yuan, up 27.2% year-on-year, while net profit was 317 million yuan, a decrease of 16.4% [1] Business Analysis - The HNB business is expected to contribute significantly to revenue, with the HNB product "hilo" launched in Japan and Poland, leading to strong sales [1] - The vaping business is projected to see double-digit growth in Q3 2025, benefiting from regulatory changes in Europe and increased enforcement against illegal products in the U.S. [1] - The company is focusing on brand development and market expansion, with a steady increase in market share for its own brands [1] - The adjusted net profit for Q3 2025 showed a year-on-year increase of 4.0% to 444 million yuan, with an adjusted net profit margin of 10.6% [1] Growth Outlook - The expansion of the legal vaping market in Europe and the U.S. is expected to continue, with the HNB product "glo hilo" gaining traction in Poland [2] - The company is positioned uniquely in the market as a supplier in both vaping and HNB categories, indicating a strong growth potential [2] Earnings Forecast and Valuation - The company forecasts EPS of 0.22, 0.39, and 0.59 yuan for 2025-2027, with corresponding PE ratios of 67, 37, and 25 times [2]

Group 1 - The company reported Q3 2025 financial data, with revenue of 4.197 billion yuan, a year-on-year increase of 27.5%, and adjusted profit of 444 million yuan, a year-on-year increase of 4.8% [1] - HNB is expected to become a major growth driver, with significant revenue increase anticipated due to the pre-production nature and the full rollout of hilo in Japan, leading to substantial sequential growth in sales [1] - The ODM+ strategy has been further validated, with satisfactory growth from new product iterations, and overall growth expected to exceed double digits as new compliant products are launched [1] Group 2 - Emerging businesses are expected to elevate the company's valuation, with the subsidiary successfully submitting an ANDA for Breo Ellipta, which is used for asthma and COPD treatment, indicating potential for further valuation uplift [1] - The company anticipates that HNB will become a primary source of profit release by 2026, with traditional vaping business valuation solidifying [2] - Revenue projections for 2025-2027 are 14.2 billion, 16.9 billion, and 19.5 billion yuan, with corresponding net profits of 1.395 billion, 1.898 billion, and 2.368 billion yuan, leading to PE ratios of 64.53x, 47.44x, and 38.02x respectively, maintaining a "buy" rating [2]